This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2025
  • /
  • 1
  • /
  • NICE Updates Guidance on Ondexxya
News

NICE Updates Guidance on Ondexxya

Read time: 1 mins
Published:19th Jan 2025
"

NICE (UK): Andexanet alfa is recommended as an option for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding, only if: i) the bleed is in the gastrointestinal tract, and ii) the company provides andexanet alfa according to the commercial arrangement.

This recommendation has been updated and replaced by NICE's technology appraisal guidance on andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal). Why the committee made these recommendations: Apixaban and rivaroxaban are anticoagulants used for preventing and treating thromboembolism (blood clots). They can increase the risk of major bleeding, which may be life-threatening. If someone has a major bleed the anticoagulation effects need to be reversed. Andexanet alfa aims to reverse the effects of apixaban and rivaroxaban, in case of uncontrolled or life-threatening bleeding. There is no clinical trial evidence directly comparing andexanet alfa with existing treatments, including prothrombin complex concentrate. An indirect comparison suggests that andexanet alfa improves survival in people with gastrointestinal bleeding or ICH, but lowers survival for people with bleeds in other parts of the body. However, there are differences between the populations in the 2 studies, so the results of the indirect comparison are uncertain. There is no robust evidence that andexanet alfa reduces long-term disability in ICH. Because of the limitations of the clinical evidence, the cost-effectiveness estimates for andexanet alfa are uncertain. They are likely to be within what NICE considers a cost-effective use of NHS resources for gastrointestinal bleeding, but not for ICH or bleeds in other parts of the body. Therefore, andexanet alfa for reversing anticoagulation is recommended for routine use only in gastrointestinal bleeding.

NICE is unable to make a recommendation about the use in the NHS of andexanet alfa (Ondexxya) for reversing anticoagulation in adults with intracranial haemorrhage. This is because AstraZeneca did not provide an evidence submission. 

Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal). This terminated appraisal partially updates and replaces NICE technology appraisal guidance 697 on andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban.

Condition: Antidote
Type: drug
How do you prefer to access medical updates and information?

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.